Cytomegalovirus Infection Market Forecast | 2023-28

Market Insights

The Global Cytomegalovirus Infection Market is estimated to grow from USD 590.91 million in 2022 to USD 845.36 million by 2028 at a CAGR of 6.10% during the forecast period.

Wish to get a sample report? Click here.

What is Cytomegalovirus (CMV) infection?

Cytomegalovirus (CMV) infection is a common herpes virus infection with various symptoms that occurs in people of all types of ages worldwide. This viral infection is communicable and can be easily spread through bodily fluids including urine, semen, blood, and breast milk. This infection can be spread easily through urine or saliva and the people infected with this virus may have the virus in the urine or saliva for months. The diseases can further be transferred from pregnant women to the baby during the delivery. Blood transfusion and infected organ transplant is another mode of disease transmission. 

Key Players

Key players operating in the global cytomegalovirus (CMV) infection market are-

• ViroPharma (The US),
• Chimerix, Inc. (The US),
• Vical, Inc. (The US),
• AiCuris Anti-infective Cures GmbH (Germany),
• Merck & Co., Inc. (The US),
• GlaxoSmithKline plc (UK),
• F. Hoffmann-La Roche AG (Switzerland),
• Clinigen Group PLC (UK),
• Fresenius Kabi Canada (Canada),
• Genentech Inc. (The US), and
• Gilead Sciences (The US).

Market Dynamics

The market is driven by a host of factors, some of which are noted below:

• Growing prevalence of CMV infection as a result of population growth and changing lifestyles.
• A rising understanding of CMV infection, including its diagnosis and available treatments.
• Increasing demand for improved diagnostic tools to identify CMV infections early on.
• Introduction of novel medications and therapeutic approaches to address CMV infection.
• Advancements in diagnostic technology can aid in early diagnosis and treatment.

Segment Analysis

Drug Type Trends

Based on drug type, the global cytomegalovirus (CMV) infection market has been segmented into cidofovir, foscarnet, valganciclovir, and ganciclovir.

• Among these, the ganciclovir segment held the highest market share in 2022 and is likely to register a healthy CAGR during the review period.
• This is mainly ascribed to the widespread usage of this drug as an anti-viral medicine to prevent and treat numerous infections. Also, it is highly effective and shows quick results.

Regional Trends

By region, the North American market garnered the largest market share in 2022 and is likely to register a considerable CAGR during the review period. This can be attributed to the high cost and better treatment in the US, extensive government funding, the strong regulatory framework for promoting cellular therapy development, and the presence of a large number of key biotechnology companies, thus accelerating regional market growth. 

COVID-19 Impact on Global Cytomegalovirus (CMV) Infection Market

The COVID-19 pandemic has substantially affected the cytomegalovirus infection industry due to a lack of patient visits to healthcare facilities such as hospitals and clinics on account of restricted movement and strict social distance norms. Moreover, due to the rising spread of coronavirus, there is a limited workforce causing staffing issues. This further affects the cytomegalovirus infection market by canceling appointments for primary care at clinics.

Critical Questions Answered in the Report

• What are the key trends in the global cytomegalovirus infection market?
• How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
• What is the impact of COVID-19 on the global cytomegalovirus infection market?
• What are the key strategies adopted by the major vendors to lead in the global cytomegalovirus infection market?
• What is the market share of the top vendors?

Get the full scope of the report. Register Here

Target Audience

Here is the list of the group of customers that the Cytomegalovirus infection market hopes to have the greatest opportunity to convert-

• Cytomegalovirus Infection treatment companies
• Hospitals
• Diagnostic Centers And Laboratories
• Academic Institutions
• Research Centers & Organizations

Research Methodology

This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.

More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles have been leveraged to gather the data.

We conducted more than 10 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both qualitative and quantitative insights.

Report Features

This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market. 

What Deliverables Will You Get in this Report?

Customization Options

Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to three players)
• SWOT analysis of key players (up to three players)

Competitive Benchmarking

Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances

Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.